Pazopanib HCl (GW786034 HCl)

Catalog No.S1035

Pazopanib HCl (GW786034 HCl) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.

Price Stock Quantity  
USD 191 In stock
USD 147 In stock
USD 270 In stock
USD 370 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Pazopanib HCl (GW786034 HCl) Chemical Structure

Pazopanib HCl (GW786034 HCl) Chemical Structure
Molecular Weight: 473.98

Validation & Quality Control

3 customer reviews :

Quality Control & MSDS

Related Compound Libraries

Pazopanib HCl (GW786034 HCl) is available in the following compound libraries:

VEGFR Inhibitors with Unique Features

Product Information

  • Compare VEGFR Inhibitors
    Compare VEGFR Products
  • Research Area
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description Pazopanib HCl (GW786034 HCl) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.
Targets VEGFR1 [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
VEGFR3 [1]
(Cell-free assay)
FGFR [1]
(Cell-free assay)

 View  More

IC50 10 nM 30 nM 47 nM 74 nM
In vitro Pazopanib potently inhibits VEGF-induced phosphorylation of VEGFR2 in HUVEC cells with IC50 of 8 nM. [1] Pazopanib shows dose-dependent growth inhibition in all synovial sarcoma cell lines including SYO-1 and HS-SY-II cells. Proliferation of SYO-1 and HS-SY-II cells is inhibited even at 1 µg/mL of Pazopanib and is completely abolished at 5 µg/mL. Pazopanib induces G1 arrest, and thereby suppresses the growth of synovial sarcoma cells. Phosphorylation of Akts, GSK-3β, JNKs, p70 S6 Kinase, and mTOR is suppressed in Pazopanib-treated SYO-1 cells compared with that in the vehicle-treated cells. [2] Pazopanib between 20 m g/mL and 22.5 m g/mL shows an increasing reduction of RPE cell viability. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
HUVECM2ewZWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7NYm2[ZNlcW6qaXLpeJMhfGinIG\FS2YucW6mdXPl[EBxem:uaX\ldoF1cW:wIH;mJGhWXkWFcx?=MXOxPFYzODN6Mh?=
HUVECMYPLbY5ie2ViYYPzZZk>Ml;PbY5pcWKrdIOgWmVITi2rbnT1Z4VlKHCqb4PwbI9zgWyjdHnvckBw\iCYRVfGVk0zKGmwIFjVWmVEKGOnbHzzJJdqfGhiYX6gTWM2OCCxZjFijNw5KG6PNELtVHYyQDZ{MEO4Ni=>
MMNY\QZ5p2U2mwYYPlJIF{e2G7NV;qTVVHcW6qaXLpeJMhXkWJRj3pcoR2[2WmIIDoc5NxcG:{eXzheIlwdiCxZjDmcJQyM4PBXlE4OTZ2M{Oy
MM.1SM1\rZmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7MmPkNVAh|rypL33MNVLrfHNpcW6qaXLpeJMhVU1iQ3XscEBIem:5dHi=NWLYbWc5OTdzNkSzN|I>
MM.1RM3Lae2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7MV2xNEDPxGdxbVy=NIX3V5NqdmirYnn0d{BOVSCFZXzsJGdzd3e2aB?=M17aUVE4OTZ2M{Oy
RPMINUi0O|lYT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm=NY\Xc2toOTBizsznM41NMn7wbY5pcWKrdIOgUW0hS2WubDDHdo94fGh?M2\td|E4OTZ2M{Oy
Dox40Mm\qS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?MVWxNEDPxGdxbVy=MXnpcohq[mm2czDNUUBE\WyuIFfyc5d1cA>?NVW1eHVZOTdzNkSzN|I>
INA-6MUPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?Mn7JNVAh|rypL33MMn7ZbY5pcWKrdIOgUW0hS2WubDDHdo94fGh?NVHldXBUOTdzNkSzN|I>
OPM2Mme2S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?M4D6clExKM7:Zz;tUC=>M3XWbIlvcGmkaYTzJG1OKEOnbHygS5Jwf3SqM3TMTlE4OTZ2M{Oy
U266M1r4Rmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7MofwNVAh|rypL33MNWnBXJRWcW6qaXLpeJMhVU1iQ3XscEBIem:5dHi=MnPPNVcyPjR|M{K=
MM.1SM2rkboN6fG:2b4jpZ4l1gSCjc4PhfS=>NHXtc3gzOCEQvHevcWw>MYHpcohq[mm2czDNUUBE\WyuIGP1dpZqfmGuM3TvSlE4OTZ2M{Oy
MM.1RMoLLZ5l1d3SxeHnjbZR6KGG|c3H5MXGyNEDPxGdxbVy=MlT3bY5pcWKrdIOgUW0hS2WubDDTeZJ3cX[jbB?=MVyxO|E3PDN|Mh?=
RPMIM1KxS4N6fG:2b4jpZ4l1gSCjc4PhfS=>MlnmNlAh|rypL33MMXzpcohq[mm2czDNUUBE\WyuIGP1dpZqfmGuMnLBNVcyPjR|M{K=
Dox40MX3jfZRwfG:6aXPpeJkh[XO|YYm=NXrMeGFIOjBizsznM41NNHnIc4lqdmirYnn0d{BOVSCFZXzsJHN2en[rdnHsM3;LVVE4OTZ2M{Oy
INA-6NVfmUng{[3m2b4TvfIlkcXS7IHHzd4F6NH7LepozOCEQvHevcWw>NF\SSXFqdmirYnn0d{BOVSCFZXzsJHN2en[rdnHsM13OdlE4OTZ2M{Oy
OPM2NWDNeHlC[3m2b4TvfIlkcXS7IHHzd4F6NI\VcpQzOCEQvHevcWw>MVjpcohq[mm2czDNUUBE\WyuIGP1dpZqfmGuMmj3NVcyPjR|M{K=
U266M2fU[oN6fG:2b4jpZ4l1gSCjc4PhfS=>MVWyNEDPxGdxbVy=MkewbY5pcWKrdIOgUW0hS2WubDDTeZJ3cX[jbB?=M2f5PFE4OTZ2M{Oy
MM.1SMnHMSpVv[3Srb36gZZN{[Xl?M2PReZN2eHC{ZYPz[ZMhXkWJRj3JcoR2[2WmIFXu[I91cGWuaXHsJGNmdGxiUILvcIln\XKjdHnvckBidmRiTXnndoF1cW:wLh?=MonxNVcyPjR|M{K=
MM.1RNWTmXo1{TnWwY4Tpc44h[XO|YYm=NInGSoh{fXCycnXzd4V{KF[HR1[tTY5lfWOnZDDFcoRwfGinbHnhcEBE\WyuIGDyc4xq\mW{YYTpc44h[W6mIF3p[5JifGmxbj6=MVSxO|E3PDN|Mh?=
Dox40MVjGeY5kfGmxbjDhd5NigQ>?NEC5eYl{fXCycnXzd4V{KF[HR1[tTY5lfWOnZDDFcoRwfGinbHnhcEBE\WyuIGDyc4xq\mW{YYTpc44h[W6mIF3p[5JifGmxbj6=Ml7BNVcyPjR|M{K=
OPM2MXLGeY5kfGmxbjDhd5NigQ>?NGntdGZ{fXCycnXzd4V{KF[HR1[tTY5lfWOnZDDFcoRwfGinbHnhcEBE\WyuIGDyc4xq\mW{YYTpc44h[W6mIF3p[5JifGmxbj6=NFPKbWcyPzF4NEOzNi=>
HBMECMmTyS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?NWK5cJhJhjFyIN88US=>M4PKcGROW09?NF3C[4tKSzVyPUGg{txONF;MZ3YzOTB6MU[1Oi=>
HBMECNIjKc3lHfW6ldHnvckBie3OjeR?=M4Locp4yKM7:TR?=NXfZdHM{TE2VTx?=M2HGfoFjem:pYYTld{B1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIG\FS2ZTOiC5aYToJIRqe3K3cITpc44hd2ZiZH;3cpN1emWjbTDQUGPPuzF?M33sZlIyODhzNkW2
HBMECNEfPbXRHfW6ldHnvckBie3OjeR?=MkjoglEh|ryPNEmzd4dFVVORNIHrW4llcXO{dYD0d{B1cGViUnHzMXJi\i2HUlugdIF1cHejeTD0bJJwfWeqIHTlZ5Jm[XOnZDDwbI9{eGixconsZZRm\CCPRVuxM|Ih[W6mIFXST|EwOg>?MXiyNVA5OTZ3Nh?=
HBMECMmXWSpVv[3Srb36gZZN{[Xl?MXn+NlAh|ryPMX;EUXNQNUjCdlJt\Gm|coXweJMhPTBnIH;mJJR2[mViZn;ycYF1cW:wIHH0JFEh|ryPM4T0WlIyODhzNkW2
MDA-MB-231MVLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?NEjxNFJ,OTBizszNNWLkWJp7TE2VTx?=M3fHfmlEPTB;NTFOwG0>MV:yNVA5OTZ3Nh?=
MDA-MB-231M1T2OGZ2dmO2aX;uJIF{e2G7NGDOUpcxNjVizszNMVTEUXNQMl6wbY5pcWKrdIOgeIhmKEWUS{GvNkB{cWewYXzpcocheGG2aIfhfS=>M3W1UVIyODhzNkW2
MDA-MB-231MVnGeY5kfGmxbjDhd5NigQ>?M3LMelUh|ryPMYDEUXNQMXPpcoR2[2W|IHGgZ4VtdC2leXPs[UBienKnc4S=MX[yNVA5OTZ3Nh?=
J82M37GeYN6fG:2b4jpZ4l1gSCjc4PhfS=>NIPsZlB,OTBizszNMVjEUXNQMmjETWM2OD1{ND61O{DPxE1?NVHMc|ZnOjF3Mkm5NFA>
T24MmGwZ5l1d3SxeHnjbZR6KGG|c3H5MkS5glExKM7:TR?=MnyzSG1UVw>?M2HlOWlEPTB;NUKuOFUh|ryPMojWNlE2Ojl7MEC=
HT1376NHzWNHZkgXSxdH;4bYNqfHliYYPzZZk>M2jENZ4yOCEQvF2=M1;mVWROW09?MULJR|UxRTJ6LkKxJO69VQ>?MUGyNVUzQTlyMB?=
RT4M1zxZYN6fG:2b4jpZ4l1gSCjc4PhfS=>Mlr3glExKM7:TR?=NHLMd|JFVVORM3PZOWlEPTB;NT6xOEDPxE1?MlvhNlE2Ojl7MEC=
CRL1749NFTrW4hkgXSxdH;4bYNqfHliYYPzZZk>M{LDd54yOCEQvF2=Mnz5SG1UVw>?MlHlTWM2OD1{Mj62PUDPxE1?NV;zdJRbOjF3Mkm5NFA>
HTB9NFHueI1kgXSxdH;4bYNqfHliYYPzZZk>MX3+NVAh|ryPMmTJSG1UVw>?M1zme2lEPTB;MUGuPFQh|ryPMnXTNlE2Ojl7MEC=
SupMkmwZ5l1d3SxeHnjbZR6KGG|c3H5NYf1VnFbhjFyIN88US=>MXjEUXNQMor3TWM2OD13Mz6zNkDPxE1?MkXVNlE2Ojl7MEC=
HTB3MXzjfZRwfG:6aXPpeJkh[XO|YYm=M3jzPJ4yOCEQvF2=MU\EUXNQMoXXTWM2OD1zND6xOkDPxE1?MVyyNVUzQTlyMB?=
CECM3T6RmZ2dmO2aX;uJIF{e2G7NVTqeVcxhjFyIN88[{9uVA>?MV3EUXNQMUjkc5dvNXKnZ4XsZZRmeyCYRVfGJIxmfmWucx?=NEXu[3QzOTZ{MEiyNi=>
RPEM{XZZWZ2dmO2aX;uJIF{e2G7M{fLeZ4yOCEQvHevcWw>MYjEUXNQNH3FSXBld3ewLYLl[5Vt[XSnczDWSWdHKGyndnXsdy=>M176[VIyPjJyOEKy
CECNYWxOFY1TnWwY4Tpc44h[XO|YYm=MX3+OUDPxGdxbVy=NYK5NXZPTE2VTx?=NUDEV|R2[myxY3vzJIVv\G:2aHXsbYFtKGOnbHygcYloemG2aX;uNGDTZZczOTZ{MEiyNi=>
5637MWLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?NF\QTotFVVORNE\qVnRKSzVyPUG1MlDjiIoQvF2=NV3FUXdkOjN6OEe2NFU>
J82NEHHTGRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=MoPzSG1UVw>?MXHJR|UxRTF6LkVihKnPxE1?M3O1TFI{QDh5NkC1
5637NH3ldnRCfXSxcHjh[5kh[XO|YYm=MUOyNEDPxE1?NFzGepNFVVORM{C0fpRzcWepZYLzJJRp\SCjdYTvdIhi\2mlIIDyc4Nme3N?MWCyN|g5PzZyNR?=
J82MXnBeZRweGijZ4mgZZN{[Xl?MWeyNEDPxE1?MVvEUXNQMVT0dolo\2W{czD0bIUh[XW2b4DoZYdq[yCycn;j[ZN{NGXvZo8zOzh6N{[wOS=>
5637MUTGeY5kfGmxbjDhd5NigQ>?NFvJeYUzOCEQvF2=MUXEUXNQMXXpcoR2[2W|IHz5d49{d22jbD3k[ZBmdmSnboSgcoVkem:|aYO=MoHVNlM5QDd4MEW=
J82Mm\sSpVv[3Srb36gZZN{[Xl?M3PzflIxKM7:TR?=MmfUSG1UVw>?NYj4eYp3cW6mdXPld{BtgXOxc3;tZYwu\GWyZX7k[Y51KG6nY4Lvd4l{NH;NfIkzOzh6N{[wOS=>
5637MYfGeY5kfGmxbjDhd5NigQ>?NH22NoUzOCEQvF2=M17kPGROW09?MWXpcoR2[2W|IHz5d49{d22nIHHseIVz[XSrb36gZY5lKGmwaHnibZR{KEOEIHHjeIl3cXS7NYDiRWlwOjN6OEe2NFU>
J82M3;3bWZ2dmO2aX;uJIF{e2G7NILO[YIzOCEQvF2=MYXEUXNQNWDsO4VzcW6mdXPld{BtgXOxc3;t[UBidHSncnH0bY9vKGGwZDDpcohq[mm2czDDRkBi[3Srdnn0fS=>NXjp[G5DOjN6OEe2NFU>
KATO-IIMnPMS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?Mn\YOUDPxE1?NEHDNm1FVVORMoXZZoxw[2u|IIDyc4xq\mW{YYTpc44>NVPOVZVSOjV{NEm1OVc>
OCUM-2MNV;PPVQ{T3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm=M4H6NFUh|ryPNVf1WZdsTE2VTx?=NEPXfJRjdG:la4OgdJJwdGmoZYLheIlwdg>?MnzJNlUzPDl3NUe=
SNU-16NFTubXVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=NIDYWWQ2KM7:TR?=NGfvTmhFVVORNYLTWWFo[myxY3vzJJBzd2yrZnXyZZRqd25?NWf1b4lTOjV{NEm1OVc>
HSC-39NFv5R|RIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=NYfINIxSPSEQvF2=MXPEUXNQNWPte|Bo[myxY3vzJJBzd2yrZnXyZZRqd25?NIGwfGszPTJ2OUW1Oy=>
KATO-IIMlO0Z5l1d3SxeHnjbZR6KGG|c3H5MXv+NVAh|ryPM{PXXmROW09?MV3JR|UxRTBwMTD0c{AzNjBizsztc4wwVA>?MXiyOVI1QTV3Nx?=
OCUM-2MNIDiS2xkgXSxdH;4bYNqfHliYYPzZZk>M{LtR54yOCEQvF2=MkjsSG1UVw>?MojTTWM2OD1yLkGgeI8hOi5yIN88cY9tN0x?M2fSelI2OjR7NUW3
SNU-16Mni4Z5l1d3SxeHnjbZR6KGG|c3H5MXv+NVAh|ryPMn7OSG1UVw>?NGn2TJlKSzVyPUCuNUB1dyB{LkCg{txud2xxTB?=MWGyOVI1QTV3Nx?=
HSC-39M{DDUIN6fG:2b4jpZ4l1gSCjc4PhfS=>NV\FVVluhjFyIN88US=>MX\EUXNQNH7wdFFKSzVyPUCuNUB1dyB{LkCg{txud2xxTB?=NHO0blEzPTJ2OUW1Oy=>
NIH 3T3M1H0bmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7M{ewfJ4yOCEQvF2=MoGzSG1UVw>?NEXPRXNqdmirYnn0d{Bk\WyuIHfyc5d1cCCjbnSgZ49td267IH\vdo1ifGmxbh?=NUewPHhHOjV{NEm1OVc>
KATO-IIIM17TUWZ2dmO2aX;uJIF{e2G7NGniUXMyKM7:TR?=MljwSG1UVw>?MnPFbY5lfWOnczDj[YxtNWO7Y3zlJIFzemW|dB?=NV7vN2cyOjV{NEm1OVc>
OCUM-2MNH;6emxHfW6ldHnvckBie3OjeR?=MVGxJO69VQ>?NFr5fHhFVVORMoHEbY5lfWOnczDj[YxtNWO7Y3zlJIFzemW|dB?=MVeyOVI1QTV3Nx?=
KATO-IIINVfZUFl{SXCxcITvd4l{KGG|c3H5MV[xJO69VQ>?NULPU5JrTE2VTx?=NI\P[XpqdmS3Y3XzJIFxd3C2b4Ppdy=>MnLkNlUzPDl3NUe=
OCUM-2MMn;yRZBweHSxc3nzJIF{e2G7MV:xJO69VQ>?M1zzN2ROW09?MYnpcoR2[2W|IHHwc5B1d3Orcx?=M{XQS|I2OjR7NUW3
KATO-IIIMU\GeY5kfGmxbjDhd5NigQ>?NIXueXAyKM7:TR?=MmDzSG1UVw>?M2KwVIlvcGmkaYTzJGZITlJ{IIDoc5NxcG:{eXzheIlwdiCjbnSg[I94dnO2cnXhcUB{cWewYXzpcochdW:uZXP1cIV{NXfCSYtFOjV{NEm1OVc>

... Click to View More Cell Line Experimental Data

In vivo The mice treated with 30 mg/kg or 100 mg/kg Pazopanib reveals a significant decrease in tumor burden compared with the mice treated with vehicle or 10 mg/kg Pazopanib. Treatment with Pazopanib is well-tolerated and there is no significant difference in the body weight among the mice in each group. [2]
Features A multi-kinase inhibitor.

Protocol(Only for Reference)

Kinase Assay:

[1]

Kinase enzyme assays VEGFR enzyme assays for VEGGR1, VEGFR2, and VEGFR3 are run in homogeneous time-resolved fluorescence (HTRF) format in 384-well microtiter plates using a purified, baculovirus-expressed glutathione-S-transferase (GST) fusion protein encoding the catalytic c-terminus of human VEGFR receptor kinases 1, 2, or 3. Reactions are initiated by the addition of 10 μL of activated VEGFR2 kinase solution [final concentration, 1 nM enzyme in 0.1 M HEPES, pH 7.5, containing 0.1 mg/mL bovine serum albumin (BSA), 300 μM dithiothreitol (DTT)] to 10 μL substrate solution [final concentration, 360 nM peptide, (biotin-aminohexyl-EEEEYFELVAKKKK-NH2), 75 μM ATP, 10 μM MgCl2], and 1 μL of titrated Pazopanib in DMSO. Plates are incubated at room temperature for 60 min, and then the reaction is quenched by the addition of 20 μL of 100 mM ethylene diamine tetraacetic acid (EDTA). After quenching, 20 μL HTRF reagents (final concentration, 15 nM Streptavidin-linked allophycocyanin, 1 nM Europium-labeled antiphosphotyrosine antibody diluted in 0.1 mg/mL BSA, 0.1 M HEPES, pH 7.5) is added and the plates incubated for a minimum of 10 min. The fluorescence at 665 nM is measured with a Wallac Victor plate reader using a time delay of 50 μs.

Cell Assay:

[1]

Cell lines HUVEC cells
Concentrations 0-10 μM
Incubation Time 1 hour
Method

Phosphorylation of VEGFR2 is assessed in HUVEC stimulated with VEGF. HUVEC are plated in type-I collagen-coated 10 cm plates in Clonetics EGM-MV medium at 1.0-1.5 × 106 cells/plate. After 24 hours, the confluent cells are serum starved overnight by replacing the growth medium with Clonetics EBM medium containing 0.1% BSA, 500 μg/mL hydrocortisone. Cells are treated with Pazopanib at various concentrations for 1 hour, followed by addition of 10 ng/mL VEGF or vehicle for 10 min. Cells are solubilized in lysis buffer. VEGFR2 is immunoprecipitated using antiflk-1 antibody and analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) followed by Western blotting and detection with antiflk-1 or with antiphosphotyrosine (anti-P-tyr-biotin) antibody. The VEGFR2 phosphorylation level is quantified by densitometry and normalized to the total VEGFR2 level.

Animal Study:

[2]

Animal Models Immunodeficient mice bearing SYO-1 cells
Formulation
Dosages 0 mg/kg, 10 mg/kg, 30 mg/kg, or 100 mg/kg
Administration Oral administration

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Harris PA, et al. J Med Chem. 2008, 51(15), 4632-4640.

[2] Hosaka S, et al. J Orthop Res. 2012.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-30)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02342600 Not yet recruiting Gastrointestinal Stromal Tumors Sarcoma Alliance for Research through Collaboration|Novartis January 2017 Phase 2
NCT02810756 Not yet recruiting Pharmacokinetics of Pazopanib The Netherlands Cancer Institute September 2016 Phase 0
NCT02348398 Not yet recruiting Cervical Cancer M.D. Anderson Cancer Center|GlaxoSmithKline August 2016 Phase 2
NCT02795819 Recruiting Renal Cell Carcinoma|Soft Tissue Sarcoma|Metastatic Disease Virginia Commonwealth University|Arno Therapeutics|Nation  ...more Virginia Commonwealth University|Arno Therapeutics|National Cancer Institute (NCI) July 2016 Phase 1
NCT02691767 Not yet recruiting Refractory Solid Tumors Samsung Medical Center May 2016 --

view more

Chemical Information

Download Pazopanib HCl (GW786034 HCl) SDF
Molecular Weight (MW) 473.98
Formula

C21H23N7O2S.HCl

CAS No. 635702-64-6
Storage 3 years -20℃powder
2 years -80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 17 mg/mL (35.86 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 30% PEG400+0.5% Tween80+5% propylene glycol 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 5-(4-((2,3-dimethyl-2H-indazol-6-yl)(methyl)amino)pyrimidin-2-ylamino)-2-methylbenzenesulfonamide hydrochloride

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related VEGFR Products

  • SU5402

    SU5402 is a potent multi-targeted receptor tyrosine kinase inhibitor with IC50 of 20 nM, 30 nM, and 510 nM for VEGFR2, FGFR1, and PDGF-Rβ, respectively.

  • Erlotinib

    Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.

  • R428 (BGB324)

    R428 (BGB324) is an inhibitor of Axl with IC50 of 14 nM, >100-fold selective for Axl versus Abl. Selectivty for Axl is also greater than Mer and Tyro3 (50-to-100- fold more selective) and InsR, EGFR, HER2, and PDGFRβ (100- fold more selective).

  • Regorafenib (BAY 73-4506)

    Regorafenib (BAY 73-4506) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM in cell-free assays, respectively.

  • Axitinib

    Axitinib is a multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ and c-Kit with IC50 of 0.1 nM, 0.2 nM, 0.1-0.3 nM, 1.6 nM and 1.7 nM in Porcine aorta endothelial cells, respectively.

    Features:Superior as second-line therapy relative to sorafenib (current standard-of-care).

  • Cabozantinib (XL184, BMS-907351)

    Cabozantinib (XL184, BMS-907351) is a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2, and AXL with IC50 of 1.3 nM, 4 nM, 4.6 nM, 12 nM/11.3 nM/6 nM, 14.3 nM and 7 nM in cell-free assays, respectively.

  • Nintedanib (BIBF 1120)

    Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50 of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM in cell-free assays. Phase 3.

  • Vandetanib (ZD6474)

    Vandetanib (ZD6474) is a potent inhibitor of VEGFR2 with IC50 of 40 nM in a cell-free assay.

  • Lenvatinib (E7080)

    Lenvatinib (E7080) is a multi-target inhibitor, mostly for VEGFR2(KDR)/VEGFR3(Flt-4) with IC50 of 4 nM/5.2 nM, less potent against VEGFR1/Flt-1, ~10-fold more selective for VEGFR2/3 against FGFR1, PDGFRα/β in cell-free assays. Phase 3.

  • Pazopanib

    Pazopanib is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFR, FGFR, c-Kit and c-Fms with IC50 of 10 nM, 30 nM, 47 nM, 84 nM, 74 nM, 140 nM and 146 nM in cell-free assays, respectively.

Recently Viewed Items

Tags: buy Pazopanib HCl (GW786034 HCl) | Pazopanib HCl (GW786034 HCl) ic50 | Pazopanib HCl (GW786034 HCl) price | Pazopanib HCl (GW786034 HCl) cost | Pazopanib HCl (GW786034 HCl) solubility dmso | Pazopanib HCl (GW786034 HCl) purchase | Pazopanib HCl (GW786034 HCl) manufacturer | Pazopanib HCl (GW786034 HCl) research buy | Pazopanib HCl (GW786034 HCl) order | Pazopanib HCl (GW786034 HCl) mouse | Pazopanib HCl (GW786034 HCl) chemical structure | Pazopanib HCl (GW786034 HCl) mw | Pazopanib HCl (GW786034 HCl) molecular weight | Pazopanib HCl (GW786034 HCl) datasheet | Pazopanib HCl (GW786034 HCl) supplier | Pazopanib HCl (GW786034 HCl) in vitro | Pazopanib HCl (GW786034 HCl) cell line | Pazopanib HCl (GW786034 HCl) concentration | Pazopanib HCl (GW786034 HCl) nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us